Click here to learn about Academy events, publications and initiatives around COVID-19.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

Our site is under planned maintenance. At this time, you will not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

Support The World's Smartest Network
×

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

DONATE
This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.


Redirected Immune Cell Therapies

Redirected Immune Cell Therapies

Tuesday, September 14, 2021, 10:30 AM - 5:30 PM EDT

Webinar

Presented By

Biochemical Pharmacology Discussion Group

The New York Academy of Sciences

 

Advances in cancer immunotherapy have demonstrated the critical role T-cells play in mediating anti-cancer effects. Emerging science highlights the expanding repertoire of potentially therapeutic immune cells—for example, macrophages and Natural Killer (NK) cells—as well as the strategies employed for immune cell redirection through innovative format design.  While recent clinical advances in T-cell engager (TcE) based treatment of liquid tumors like blinatumomab have heightened expectations for such approaches, multiple questions and challenges remain en route to realizing the full therapeutic potential of redirecting immune cells in the treatment of neoplasms and other diseases.

This symposium will explore basic insights regarding immune-cell trafficking and immunological signaling; multispecific antibody design features enabling optimal biodistribution and activity in target tissues (e.g. solid tumors); and experimental and pharmacokinetic/pharmacodynamic models for more confident clinical translation. It will bring together a cross-disciplinary representation of thought leaders from the immunology, oncology, imaging/microscopy, pharmacometrics and protein engineering fields to not only consider open questions but also propose research toward game-changing breakthroughs.

Call for Abstracts

You are invited to submit a poster abstract to be considered for a virtual poster session and short talks. For submission instructions, please visit our online portal here. The deadline for abstract submission is July 26, 2021.

Keynote Speaker

Koustubh Ranade, PhD

Immunocore

Speakers

Tal Danino, PhD

Columbia University

Susanne Hipp, PhD

Boehringer Ingelheim

Morgan Huse, PhD

Memorial Sloan Kettering Cancer Center

Paul Parren, PhD

Lava Therapeutics

Scientific Organizing Committee

Steven Hansel, PhD

Boehringer Ingelheim

Susanne Hipp, PhD

Boehringer Ingelheim

Lance Kam, PhD

Columbia University

Alison Carley, PhD

New York Academy of Sciences